Cytokinetics, Incorporated (NASDAQ:CYTK) Director Santo J. Costa sold 5,000 shares of the company’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $14.00, for a total value of $70,000.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at $70,000. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Cytokinetics, Incorporated (NASDAQ CYTK) opened at 14.85 on Friday. The company’s market cap is $796.94 million. The company’s 50-day moving average price is $13.42 and its 200 day moving average price is $13.25. Cytokinetics, Incorporated has a 52 week low of $8.51 and a 52 week high of $17.20.

Cytokinetics, (NASDAQ:CYTK) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by $0.03. The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $5.28 million. Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 14.15%. On average, analysts anticipate that Cytokinetics, Incorporated will post ($2.46) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Santo J. Costa Sells 5,000 Shares of Cytokinetics, Incorporated (CYTK) Stock” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/01/santo-j-costa-sells-5000-shares-of-cytokinetics-incorporated-cytk-stock.html.

Several large investors have recently added to or reduced their stakes in CYTK. Airain ltd boosted its stake in shares of Cytokinetics, by 91.5% in the first quarter. Airain ltd now owns 41,748 shares of the biopharmaceutical company’s stock worth $536,000 after buying an additional 19,948 shares during the period. Trexquant Investment LP bought a new stake in shares of Cytokinetics, during the first quarter worth approximately $802,000. Nine Chapters Capital Management LLC bought a new stake in shares of Cytokinetics, during the first quarter worth approximately $265,000. Parametric Portfolio Associates LLC boosted its stake in shares of Cytokinetics, by 1.4% in the first quarter. Parametric Portfolio Associates LLC now owns 13,333 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 189 shares during the period. Finally, TFS Capital LLC bought a new stake in shares of Cytokinetics, during the first quarter worth approximately $1,233,000. 71.51% of the stock is owned by institutional investors.

A number of research analysts recently commented on CYTK shares. Zacks Investment Research downgraded Cytokinetics, from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Cytokinetics, in a research note on Friday, May 19th. Morgan Stanley started coverage on Cytokinetics, in a research note on Monday, July 31st. They set an “overweight” rating and a $24.00 price objective for the company. BidaskClub upgraded Cytokinetics, from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, ValuEngine upgraded Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Three equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Cytokinetics, presently has a consensus rating of “Buy” and an average price target of $21.30.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.